In Brief | Published:

PROSTATE CANCER

PARP inhibitors synergize with abiraterone

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

    Original article

    1. Clarke, N. et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(18)30365-6 (2018)

    Download references

    Author information

    Correspondence to Peter Sidaway.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark